FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer
March 8th 2021Dr. Shitara discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.
Read More
Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
March 4th 2021John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.
Read More
Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
February 25th 2021Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.
Read More
Nichols on Navigating the Nuances of von Hippel-Lindau Disease
February 22nd 2021In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.
Read More
Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer
February 18th 2021In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.
Read More
Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer
February 15th 2021Dr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.
Read More
Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology
February 8th 2021Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.
Read More
Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer
January 28th 2021Dr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.
Read More
Capitalizing on Cellular Therapies in Lymphoma and Myeloma
January 18th 2021In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.
Read More
Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer
January 11th 2021In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.
Read More
More Innovation Is on Tap for 2021: Five Experts Describe Key Trends
January 8th 2021The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.
Read More
Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma
January 7th 2021In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with the newly diagnosed multiple myeloma and the evolving role of minimal residual disease testing.
Read More
Spotlighting Management Strategies Across Sarcoma Subtypes
January 4th 2021Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.
Read More
Lindau on Leading Successful Surgical Fellowships
December 31st 2020In our exclusive interview, Robert Lindau, III, MD, discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.
Read More
Gaining Insight Into the Management of Gastrointestinal Malignancies
December 28th 2020Faculty from a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancer hosted by the University of Kentucky discuss the current paradigms in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer.
Read More
Druker Details a Career of Determination, Patient Impact, and Family Success
December 24th 2020In our exclusive interview, Brian Druker, MD, discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.
Read More
Multimodality Therapy Makes Waves in Bladder Cancer
December 21st 2020Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.
Read More
Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC
December 17th 2020In our exclusive interview, Dr. Borghaei and Dr. Gunuganti discuss patient selection for frontline immunotherapy, combination immunotherapy, and chemoimmunotherapy in NSCLC, the importance of PD-L1 expression, and emerging agents that are coming down the pike.
Read More
Learning to Tailor Targeted and Immune Therapy in Lung Cancer
December 14th 2020Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!
Read More